daptive servo-ventilation (ASV) is primarily used for the treatment of patients with Cheyne-Stokes respiration (CSR) because it provides suitable ventilatory support using expiratory positive airway pressure and a pressure support system. 1 Several studies have reported that ASV has also been successfully used for treating central sleep apnea (CSA) and CSR in heart failure (HF) patients. 2-4 Furthermore, ASV was found to be effective for treating obstructive sleep apnea (OSA) and complex sleep apnea syndrome owing to the aforementioned advantages related to ventilatory support. [5] [6] [7] Sleep-disordered breathing (SDB) is closely related to cardiovascular disease (CVD). [8] [9] [10] [11] [12] [13] [14] It is also closely related to the incidence of fatal cardiovascular events and mortality. 15, 16 Continuous positive airway pressure (CPAP) has been effective in treating HF patients. [17] [18] [19] In contrast, a previous study showed that treatment of CSA with CPAP in HF patients decreased apnea frequency and improved blood oxygenation, norepinephrine levels, and left ventricular function, but it failed to improve transplantation-free survival. 20 In recent years, ASV therapy has been reported to be more effective than CPAP for treating HF patients with coexisting OSA and CSR. 21 For these reasons, the aim of the present study was to determine the efficacy of ASV therapy in HF by evaluating 1-year prognosis and improvement of survival rate in HF patients treated with ASV.
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Study Design and Ethics
A total of 171 consecutive HF patients underwent overnight sleep assessment after medical therapy was optimized. The average duration of the sleep study was 10.8±13.7 days. The overnight sleep study was performed after discontinuation of the inotropic or carperitide treatment. All procedures were performed at Division of Cardiology, Isesaki Municipal Hospital. Before conducting ASV, written informed consent was required, but we could not obtain written informed consent from 76 patients. The present study consisted of the 85 HF patients who presented with class II-IV symptoms, according to the New York Heart Association (NYHA) classification for the stages of HF, and who accepted initiation of ASV therapy. Regardless of the severity of SDB, ASV was initiated.
We conducted a 1-year follow-up study, and checked the patients' physical status including improvements in the left
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ventricular ejection fraction (LVEF), brain natriuretic peptide (BNP), and incidence of fatal cardiovascular events including death from progressive HF, cardioembolic stroke, and fatal cardiac arrhythmias. In terms of the definition of progressive HF, we excluded other diseases from HF and diagnosed patients who had pulmonary edema or cardiogenic shock as having progressive HF. Based on past literature, 22 the patients were classified into 2 groups based on adherence to ASV therapy. The group of patients using ASV for ≥4 h/night was designated as the good adherence group, and the other group using ASV for <4 h/night was designated as the poor adherence group. Fifty-seven patients were classified into the good adherence group and 28 into the poor adherence group. Follow-up was performed during outpatient visits over 1 year (Figure 1 ). This study was conducted in accordance with the recommendations of the Declaration of Helsinki (1975) , and the protocol was approved by Isesaki Municipal Hospital Institutional Review Board. Written informed consent was obtained from each patient at the start of the study.
Sleep Evaluation and Treatment Devices
For sleep evaluation, all patients who underwent full-night polysomnography were assessed on digital polygraphy (ESeries Plus; Compumedics, Abbotsford, Vic., Australia). Assessment included electroencephalography, electro-oculography, and chin electromyography. Chest and abdominal movements were monitored using 2 bands (Inductive Respiratory Bands). Airflow was assessed using a thermistor. Arterial oxygen saturation was measured continuously at a sampling frequency of 1 s using a pulse oximeter with a finger probe (Nonin 8000J Adult Flex Sensor). Sleep stages and arousals were scored according to standard methods. 23, 24 Apnea was defined as the complete cessation of airflow lasting ≥10 s. Hypopnea was defined as a decrease in airflow of ≥50% for ≥10 s accompanied by desaturation (3% decrease in arterial oxygen saturation) and/or an electroencephalographic arousal response. The apnea-hypopnea index (AHI) was defined as the total number of apneas and hypopneas per hour of sleep. After patients underwent full-night polysomnography, ASV was initiated in the hospital.
As for the treatment device, ASV (AutoSet-CS; ResMed, Sydney, Australia) was given using a full facemask (ResMed). It consisted of 4-cm H2O expiratory positive airway pressure and a suitable minimum-maximum inspiratory support, which was within the recommended minimum manufacturer setting range of 3-8 cmH2O. The backup respiratory rate was 15 breaths/min. Basically, the setting ranges including expiratory positive airway pressure and inspiratory support were fixed. If we found remaining apnea during ASV therapy, ASV titration was performed as necessary.
Data Collection
Baseline data included medical history, physical examination, Figure 1 . Study design. ASV, adaptive servoventilation. Prognostic Effect of ASV in HF and blood biochemistry. Before ASV, venous blood samples were obtained after overnight fasting and BNP levels were recorded. Arterial blood samples were obtained for blood gas analysis with the patients in the supine position and not receiving supplemental oxygen. Furthermore, 2-D transthoracic echocardiography was performed. The left ventricular end-diastolic and end-systolic dimensions were measured on M-mode echocardiography, and LVEF was calculated using Simpson's method before ASV therapy. Presence of dyslipidemia was defined as recent use of cholesterol-lowering drugs, triglycerides ≥150 mg/dl, low-density lipoprotein cholesterol ≥140 mg/dl, and/or high-density lipoprotein cholesterol <40 mg/dl. Presence of hypertension was defined as recent use of anti-hypertensive drugs or blood pressure ≥140/90 mmHg, while that of diabetes mellitus was defined as recent use of insulin or antidiabetic drugs, fasting blood glucose ≥126 mg/dl, and/or hemoglobin A1c ≥6.5%.
After ASV therapy, the survival rate was calculated according to incidence of fatal cardiovascular events including death from progressive HF, cardioembolic stroke, and fatal cardiac arrhythmias, excluding death from other reasons.
Statistical Analysis
Continuous data are expressed as mean ± SD and were compared using 2-tailed t-test. Categorical data are expressed as counts (percentage) and were compared using a chi-squared test. The survival rate (fatal cardiovascular event-free rate) was calculated using Kaplan-Meier analysis, and a log-rank test was used to assess the differences between the 2 study groups. The association between the incidence of fatal cardiovascular events and good adherence to ASV was verified using a Cox proportional hazards model. The significance level was set at 5%, and all analyses were performed using JMP 6.0 (SAS Institute, Cary, NC, USA).
Results
The study group consisted of 85 consecutive HF patients. The mean age was 72±10 years. After treating the underlying disease in the acute phase and diagnosing SDB severity and type, these 85 patients were treated with ASV. Fifty-seven patients were classified into the good adherence group and 28 into the poor adherence group. Patient characteristics are listed in 
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TAKAMA N et al. Table 1 . No significant differences were observed between the 2 groups with respect to age, gender, body mass index, drug therapy, and history of coronary risk factors (hypertension, dyslipidemia, diabetes mellitus, and smoking). Before ASV therapy, there were no significant differences between the 2 groups with regard to LVEF (good adherence group, 41.3±17.4%; poor adherence group, 40.8±16.5%; P=0.911) or blood biochemistry, including triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, fasting blood sugar, and blood gas analysis. In contrast, significant differences were noted between the groups with regard to BNP (good adherence group, 550±462 pg/ml; poor adherence group, 938±965 pg/ml; P=0.01). Full-night polysomnography showed that AHI was equally high in the 2 groups (good adherence group, 42.6±25.7/h; poor adherence group, 36.4±19.0/h; P=0.33). In addition, the following parameters were equally high in the 2 groups: CSA index (good adherence group, 10.1±15.7/h; poor adherence group, 7.1±11.1/h; P=0.42); OSA index (good adherence group, 8.4±15.8/h; poor adherence group, 4.3±8.7/h; P=0.28); and hypopnea index (good adherence group, 19.0±13.9/h; poor adherence group, 23.6±19.5/h; P=0.28). In contrast, the cumulative percentage time at a pulse oximetry oxygen saturation <90% was greater in the good adherence group (good adherence group, 5.9±10.7/h; poor adherence group, 1.5±2.7/h; P=0.07). The oxygen desaturation index at the 4% level was significantly greater in the good adherence group (good adherence group, 26.3±15.4/h; poor adherence group, 16.8±13.0/h; P=0.02). Table 2 summarizes the parameters analyzed during Data given as n (%). ASV, adaptive servo-ventilation. Data given as mean ± SD or n (%). Abbreviations see in Tables 1,2 . Prognostic Effect of ASV in HF polysomnography. The incidence of fatal cardiovascular events including death from progressive HF, cardioembolic stroke, and fatal cardiac arrhythmias is given in Table 3 . The relationship between fatal cardiovascular events is presented in Table 4 . Figure 2 shows the survival rate (fatal cardiovascular event-free rate) in the present study as determined using Kaplan-Meier analysis; it was significantly higher in the good adherence group (P=0.0046, log-rank test). According to the Cox proportional hazards model that included adherence to ASV, the odds ratio (95% confidence interval) of fatal cardiovascular events in the good adherence group was 0.53 (0.27-0.99; P=0.046) based on the results of Table 4 and univariate analysis ( Table 5) .
Discussion
In the present study, we examined ASV therapy data from 85 HF patients to determine whether ASV improved the survival rate in these patients. The results show that ASV is effective in treating HF. Moreover, ASV also prevented fatal cardiovascular events, and had a better 1-year prognosis. Generally, CPAP is used to treat HF, and adherence is one of the most important factors for improvement in physical condition. A previous study reported that good adherence (≥4 h/night) was effective in improving patients' CVD risk, memory performance, daytime functioning, quality of life, and blood pressure. 22,25-32 Another study reported there was no difference in the percentage of nights with at least 4 h of use between bi-level positive airway pressure and CPAP. 33 In recent years, ASV has been reported to be more effective than CPAP for treating HF with coexisting OSA and CSR. 21 Based on these reports, the objective of the present study was to estimate the efficacy of ASV in treating HF patients, with patients categorized into 2 groups depending upon planned adherence to ASV (≥4 h/night and <4 h/night). The results clearly show that good adherence (≥4 h/night) improved the survival rate and had better 1-year prognosis in HF patients.
In terms of HF therapy, previous studies had a limitation in that CPAP could not be used to extend life in patients who had both CSA and HF, except in those cases in which CSA was suppressed soon after initiation. 19, 20 In contrast, it was reported that ASV has successfully improved exercise tolerance in patients with HF and CSR, and that ASV was also more effective than CPAP for treating HF patients with coexisting OSA 21,34-36 The effect of ASV on the survival of HF patients, however, has not yet been investigated. In the present study ASV prevented fatal cardiovascular events including death from progressive HF, cardioembolic stroke, and fatal cardiac arrhythmias. We thus infer that ASV improves survival in HF patients. On assessment of the critical factors determining prognosis in HF patients, BNP level was found to be one of the most important factors. 37 Before ASV, the poor adherence group had significantly higher BNP levels than the good adherence group. Thus, to determine whether pre-ASV BNP level affected the results, we also assessed multivariate predictors of fatal cardiovascular events using a Cox proportional hazards model. The results showed that pre-ASV BNP level did not affect the incidence of fatal cardiovascular events ( Table 5) .
Study Limitations
The present study had some limitations. First, this was a single-center study, and thus, selection bias was a major concern. To minimize potential selection bias, we tried to include all patients who presented with NYHA class II-IV HF symptoms. Only approximately half of all patients, however, accepted initiation of ASV therapy. Second, this study showed that ASV improved the survival rate and 1-year prognosis in HF patients. In contrast, there was no significant difference between the groups with respect to number of hospitalizations. It remains possible that ASV might have important limitations if it did not prevent the number of hospitalizations due to HF. Third, most of the HF patients were taking β-blockers before the present study. No significant difference was observed between the groups with respect to β-blocker treatment, but it might have created a major limitation. Finally, the most important limitation in the present study was the small number of patients; but, when compared with previous ASV studies, 2,5,7,21,34 it was actually quite large. Nonetheless, more studies examining a larger number of HF patients treated with ASV should be conducted to facilitate a better and more accurate estimation of the efficacy of ASV therapy in HF patients.
Conclusions
ASV therapy for HF patients facilitated a significant reduction in the incidence of fatal cardiovascular events, thus demonstrating that ASV is an effective option for treating HF. We believe that in the future, ASV will be recognized as an effective treatment option for HF, on a par with currently practiced medical therapies and techniques.
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